• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

    11/5/24 8:30:00 AM ET
    $ADIL
    $VRPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADIL alert in real time by email

    GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024.

    Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy, investor relations, and operational efficiency. Most recently, Mr. Shah served as the CFO at Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX), where he focused on implementing fundraising and strategic initiatives, managed all financial operations, and co-managed investor relations. Previously, at Aravive, Inc., Mr. Shah helped raise over $150 million and played integral roles in a major reverse merger and out-licensing efforts in China. At Pacira Pharmaceuticals, Inc., he partnered on the company's IPO, contributing to S-1 preparation, financial audits, and SEC compliance. His background also includes finance leadership roles at Cardinal Health, Inc. and Jostens Learning Corporation, where he advanced supply chain operations and international business efforts. He began his career with auditing positions at KPMG Peat Marwick and Price Waterhouse Coopers. He received his BA degree from Ranchi University in India and his MBA from Arizona State University in finance.

    "We are thrilled to welcome Vinay as our new Chief Financial Officer," said Cary Claiborne, CEO of Adial Pharmaceuticals. "Vinay brings a wealth of experience in financial strategy within the pharmaceutical industry, and his proven leadership in driving successful capital markets strategies will be invaluable as we advance AD04 and our strategic goals. Additionally, I would like to thank Joe Truluck for his numerous contributions to Adial over the years and wish him the best in his future endeavors."

    "I am excited to join the talented team at Adial Pharmaceuticals during this pivotal time," said Vinay Shah. "Adial's commitment to developing innovative treatments that address critical unmet needs aligns with my own passion for advancing impactful healthcare solutions. I look forward to contributing to Adial's growth and supporting their strategic objectives as we work to deliver value for patients, partners, and shareholders."

    On November 1, 2024, Joseph Truluck notified the CEO of the Company of his decision to resign from his position as the Company's Chief Financial Officer to pursue other opportunities. Mr. Truluck will remain CFO of the Company until November 15, 2024 and has entered into a consulting agreement with Adial, through March 31, 2025, in order to aid in an orderly transition. Mr. Truluck's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices, including any matters concerning the Company's controls or any financial or accounting-related matters or disclosures.

    About Adial Pharmaceuticals, Inc.

    Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company's ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company's proprietary companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.

    If you are interested in exploring partnership opportunities with Adial, we invite you to reach out to us ([email protected]) to discuss how our joint efforts can bring about positive change in the millions of patients who are struggling with addiction.

    Forward-Looking Statements

    This communication contains certain "forward-looking statements" within the meaning of the U.S. federal securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could" are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding the expected contribution of Mr. Shah, advancing AD04 and our strategic goals, delivering value for our patients, partners, and shareholders and the potential of AD04 to treat other addictive disorders such as opioid use disorder, gambling, and obesity. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, Mr. Shah's ability to contribute to our growth and support our strategic objectives, our ability to pursue our regulatory strategy, our ability to advance ongoing partnering discussions, our ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements, our ability to develop strategic partnership opportunities and maintain collaborations, our ability to obtain or maintain the capital or grants necessary to fund our research and development activities, our ability to complete clinical trials on time and achieve desired results and benefits as expected, regulatory limitations relating to our ability to promote or commercialize our product candidates for specific indications, acceptance of our product candidates in the marketplace and the successful development, marketing or sale of our products, our ability to maintain our license agreements, the continued maintenance and growth of our patent estate and our ability to retain our key employees or maintain our Nasdaq listing. These risks should not be construed as exhaustive and should be read together with the other cautionary statement included in our Annual Report on Form 10-K for the year ended December 31, 2023, subsequent Quarterly Reports on Form 10-Q and current reports on Form 8-K filed with the Securities and Exchange Commission. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.

    Contact:

    Crescendo Communications, LLC

    David Waldman / Alexandra Schilt

    Tel: 212-671-1020

    Email: [email protected]



    Primary Logo

    Get the next $ADIL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ADIL
    $VRPX

    CompanyDatePrice TargetRatingAnalyst
    Adial Pharmaceuticals Inc
    $ADIL
    11/14/2024$8.00Buy
    Rodman & Renshaw
    Adial Pharmaceuticals Inc
    $ADIL
    10/13/2021$12.00Buy
    Brookline Capital
    Adial Pharmaceuticals Inc
    $ADIL
    6/29/2021$5.00Buy
    Litchfield Hills
    More analyst ratings

    $ADIL
    $VRPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Newman James W. Jr.

      4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)

      6/2/25 4:01:35 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Gilliland Robertson H.

      4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)

      6/2/25 4:01:36 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Shah Vinay

      4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)

      6/2/25 4:01:34 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADIL
    $VRPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2025. Cary Claiborne, CEO of Adial Pharmaceuticals, commented, "We made meaningful progress during the first quarter of 2025, completing foundational steps that position us to advance swiftly toward the initiation of our Phase 3 clinical trial for AD04, our lead investigational drug for Alcohol Use Disorder (AUD)." "One of the key ac

      5/15/25 8:30:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study

      Glen Allen, Va., May 13, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it has received a six-figure development milestone payment from Adovate, LLC, following the commencement of a Phase 1 clinical trial evaluating Adovate's lead compound for asthma, ADO-5030. This milestone payment follows Adovate's exercise of its option to acquire the assets and business of Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, as previously disclosed. The ongoing Phase 1 study

      5/13/25 8:30:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

      Meeting to Take Place on July 25, 2025 Meeting's Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the FDA has granted Adial's request for an End of Phase 2 meeting to discuss Adial's proposed clinical development plan and seek FDA guidance on the Phase 3 adaptive with enrichment design of the upcoming clinical trial for AD04. The meeting will take place on July 25, 2025. AD04 is

      5/8/25 8:30:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADIL
    $VRPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ADIL
    $VRPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ADIL
    $VRPX
    SEC Filings

    See more
    • Amendment: SEC Form SC 13G/A filed by Adial Pharmaceuticals Inc

      SC 13G/A - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)

      11/14/24 3:44:01 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Virpax Pharmaceuticals Inc.

      SC 13G - Virpax Pharmaceuticals, Inc. (0001708331) (Subject)

      5/23/24 4:06:37 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Adial Pharmaceuticals Inc

      SC 13G - ADIAL PHARMACEUTICALS, INC. (0001513525) (Subject)

      2/14/24 3:22:13 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Adial Pharmaceuticals with a new price target

      Rodman & Renshaw initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $8.00

      11/14/24 7:21:37 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Brookline Capital initiated coverage on Adial Pharmaceuticals with a new price target

      Brookline Capital initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      10/13/21 11:54:22 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Litchfield Hills initiated coverage on Adial Pharmaceuticals with a new price target

      Litchfield Hills initiated coverage of Adial Pharmaceuticals with a rating of Buy and set a new price target of $5.00

      6/29/21 10:47:45 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-1 filed by Adial Pharmaceuticals Inc

      S-1 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

      6/6/25 8:34:48 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Adial Pharmaceuticals Inc

      S-3 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

      5/30/25 4:11:59 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - ADIAL PHARMACEUTICALS, INC. (0001513525) (Filer)

      5/30/25 4:01:23 PM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADIL
    $VRPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

      GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2024 fiscal year ended December 31, 2024. Key Highlights Successful completion of AD04-103 pharmacokinetics (PK) study of AD04, corroborating bioavailability, dose proportionality, no food effect, and safety profile consistent with the use of Ondansetron. Advancement towards pivotal Phase 3 trial design supportive of ongoing partnership

      3/4/25 8:30:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

      GLEN ALLEN, Va., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the third quarter of 2024. Cary Claiborne, President and Chief Executive Officer of Adial, stated, "We reached an important milestone this quarter with the successful database lock of the pharmacokinetics study for AD04, our lead investigational, genetically targeted therapeutic for the treatment of Alcohol Use Disorder (AUD). The pharmacokinetics study is e

      11/13/24 8:30:00 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

      GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy, investor relations, and operational efficiency. Most recently, Mr. Shah served as the CFO at Virpax Pharmaceuticals, Inc. (N

      11/5/24 8:30:00 AM ET
      $ADIL
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADIL
    $VRPX
    Financials

    Live finance-specific insights

    See more
    • Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments

      Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2024, and other recent developments. "We recently reported results for a Probudur™ Maximum Tolerated Dose Study, as we continue to make steady progress in anticipation of filing our IND. The results of this study, as expected, confirmed our belief that a single injection of Probudur was well-tolerated. Our studies to date continue to reaffirm our belief that Probu

      5/13/24 4:10:00 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Pharmaceuticals Reports 2023 Year-End Results

      Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2023, and other recent developments. "We are off to a strong start in 2024 and are pleased to have regained compliance with Nasdaq. Additionally, we have executed a settlement agreement with the Plaintiffs, and can now focus on developing our non-addictive product candidates for pain management," commented Gerald W. Bruce, Chief Executive Officer of Virpax.

      3/26/24 7:30:00 AM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments

      Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended September 30, 2023, and other recent developments. "We recently announced results from two preclinical studies for Probudur™, our lead product candidate for post operative pain, that demonstrated significantly longer efficacy in animal models than the product currently on the market today. With these solid results, we believe we are on track to file our Investigational New

      11/15/23 4:15:00 PM ET
      $VRPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ADIL
    $VRPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Schuyler Kevin bought $1,918 worth of shares (700 units at $2.74) (SEC Form 4)

      4 - ADIAL PHARMACEUTICALS, INC. (0001513525) (Issuer)

      10/3/23 8:54:38 AM ET
      $ADIL
      Biotechnology: Pharmaceutical Preparations
      Health Care